GC - GC vitamin D binding protein Gene

Species: Felis catus

Gene Type: protein coding
Gene ID: 101096313

GC Products (1)

mRNA Protein Name
XM_006931069.5 XP_006931131.3 vitamin D-binding protein
Protein Preferred Names Protein Names

vitamin D-binding protein

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-B0561 Spironolactone 99.81% Yes
HY-13693 Mometasone furoate Agonist 99.90% Yes
HY-108741 Plecanatide Agonist 99.93% Unkown
HY-17569 Difluprednate Inhibitor 99.63% Yes
HY-108741A Plecanatide acetate Agonist 99.70% Unkown

Clinical Phase

Bioactive Molecules (15)
Cat. No. Product Name Effect
Purity Phase
HY-141642 Triheptadecanoin 98.0% Phase 4
HY-109110 Avasopasem manganese 96.07% Phase 3
HY-14823 Sobetirome Agonist 99.91% Phase 2
HY-P0118B Disitertide diammonium 99.00% Phase 2
HY-10498 Lexibulin 99.10% Phase 2
HY-13336 Imisopasem manganese 96.33% Phase 2
HY-P0118 Disitertide 98.03% Phase 2
HY-14181A Cinaciguat hydrochloride Activator 98.90% Phase 2
HY-132829 Rucosopasem manganese / Phase 2
HY-114577 Palifosfamide tromethamine Chemical 98.74% Phase 2
HY-P0118A Disitertide TFA / Phase 2
HY-10498A Lexibulin dihydrochloride / Phase 2
HY-P3499 Dolcanatide Agonist 99.20% Phase 1
HY-12946 BI 653048 Inhibitor 99.84% Phase 1
HY-12946A BI 653048 phosphate Inhibitor / Phase 1
Bioactive MoleculesInhibitory Antibodies (5)
Cat. No. Product Name Effect
Purity Phase
HY-P99693 Lenvervimab Inhibitor ≥99% Phase 3
HY-P99013 Codrituzumab Inhibitor 99.07% Phase 2
HY-P99020 Fresolimumab Inhibitor 99.51% Phase 2
HY-P991571 GC1118 Inhibitor 99.22% Phase 2
HY-P991582 BI-1607 Antagonist / Phase 2

Pre-clinical Phase

Bioactive Molecules (75)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-108314A GC7 Sulfate Inhibitor 98.0% Unkown
HY-D1020 7-Aminoactinomycin D Inhibitor ≥99.0% Unkown
HY-136684 BrBzGCp2 Inhibitor 99.00% Unkown
HY-111798 Heme Oxygenase-1-IN-1 Inhibitor 99.13% Unkown
HY-141513 NH-3 Antagonist 99.41% Unkown
HY-100721 GC376 sodium Inhibitor 99.53% Unkown
HY-W127512 5β-Cholanic acid 99.87% Unkown
HY-111798A Heme Oxygenase-1-IN-1 hydrochloride Inhibitor 99.03% Unkown
HY-13963 ZCL278 Inhibitor 98.49% Unkown
HY-111208 CCT129957 Inhibitor 99.16% Unkown
HY-W040129 Chromomycin A3 99.66% Unkown
HY-108628 SU16f Inhibitor 99.36% Unkown
HY-D1191 SYBR green I chloride 98.09% Unkown
HY-132184 5,6-Epoxyeicosatrienoic acid Inhibitor 99.9% Unkown
HY-W089645 2,2,2-Trifluoro-N-methyl-N-(trimethylsilyl)acetamide 98.79% Unkown
HY-W004290 Methyl heptadecanoate 99.69% Unkown
HY-I0450 Anticancer agent 265 99.64% Unkown
HY-W004290S Methyl heptadecanoate-d33 99.52% Unkown
HY-152038 SPEN-IN-1 Inhibitor 97.25% Unkown
HY-130189 S-Phenylmercapturic acid 99.38% Unkown
HY-113422 Tetrahydrocorticosterone 99.90% Unkown
HY-149453 MCUF-651 Modulator 99.85% Unkown
HY-131389 Cholesteryl heptadecanoate 98.0% Unkown
HY-DY1099 7-Aminoactinomycin D (solution) Inhibitor / Unkown
HY-114043 NCGC00092410 Inhibitor 98.10% Unkown
HY-160178 Glucocorticoid receptor agonist-3 Ala-Ala-Mal 99.70% Unkown
HY-155789 C17 Globotriaosylceramide (d18:1/17:0) ≥99.0% Unkown
HY-108314 GC-7 Inhibitor / Unkown
HY-151482 SARS-CoV-2 Mpro-IN-2 Inhibitor 98.96% Unkown
HY-107547 BPIPP Inhibitor 98.3% Unkown
HY-B0561S4 Spironolactone-d6-1 99.26% Unkown
HY-N6651 Isocryptotanshinone ≥98.0% Unkown
HY-123023 12(S)-HETE-d8 Inducer 98.00% Unkown
HY-101282 Glutaminyl Cyclase Inhibitor 3 Inhibitor / Unkown
HY-108353S Isoprenaline-d7 acetate / Unkown
HY-111442 GC 14 Antagonist / Unkown
HY-113422S2 Tetrahydrocorticosterone-d3-1 / Unkown
HY-118274 ADDA / Unkown
HY-130229 (±)5,6-DHET lactone / Unkown
HY-13963S ZCL278-13C / Unkown
HY-141717 α-cis-Bergamotene / Unkown
HY-145381 11β-HSD1-IN-6 Inhibitor / Unkown
HY-146398 AMPK activator 6 Activator / Unkown
HY-14823G Sobetirome (GMP) Agonist / Unkown
HY-148392 Neu5Gcα(2-6) N-Glycan-Asn / Unkown
HY-149774 GC-78-HCl / Unkown
HY-156020 Glucocerebrosidase-IN-2 Inhibitor / Unkown
HY-157001 7-Deaza-dGTP tetralithium / Unkown
HY-160180 Glucocorticoid receptor agonist-4 Ala-Ala-Mal / Unkown
HY-162293 CDK8-IN-14 Inhibitor / Unkown
HY-166965 Neu5Gc(α2,6)N-Acetylgalactosamine / Unkown
HY-17569S2 Difluprednate-d3-1 Inhibitor / Unkown
HY-178738 GC-072 Inhibitor / Unkown
HY-179535 Axl-IN-21 Inhibitor / Unkown
HY-N15629 Melicopicine / Unkown
HY-N15820 C18:0 GM1(Neu5Gc) Ceramide (d18:1/18:0) / Unkown
HY-N15822 C18:0 GM3(Neu5Gc) Ceramide (d18:1/18:0) / Unkown
HY-N15823 C18:0 GM2(Neu5Gc) Ceramide (d18:1/18:0) / Unkown
HY-N18337 Salidroside 3-O-glucopyranoside / Unkown
HY-P10786 LinTT1 peptide Inhibitor / Unkown
HY-P1911 CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156) / Unkown
HY-RS05316 GC Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W127357 Tripelargonin / Unkown
HY-W127496 Methyl 13-methyltetradecanoate / Unkown
HY-W130478S 1-Phenylhexane-d5 / Unkown
HY-120410 DL-4662 / Unkown
HY-154171 Deoxyribosyl dihydropyrimido[4,5-c][1,2]oxazin-7-one 99.87% Unkown
HY-165420 GC-IN-2 Inhibitor / Unkown
HY-183956 GC813 Inhibitor / Unkown
HY-N10626 Neu5Gcα(2-6) N-Glycan / Unkown
HY-RS16765 Gc Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS20039 Il2rg Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS20738 Gba1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23205 Gc Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W099771 4-Propylanisole 99.05% Unkown
Bioactive MoleculesInhibitory Antibodies (3)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P991302 KL-A289 Inhibitor / Unkown
HY-P990844 Anti-GC1q R/C1QBP Antibody (60.11) Inhibitor / Unkown
HY-P991482 ADI-42898 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens GC NCBI NCBI:2638